Kjellin M., Wesslén T., Löfblad E., Lennerstrand J. and Lannergård A. (2018) “The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort”, Upsala Journal of Medical Sciences, 123(1), pp. 50–56. doi: 10.1080/03009734.2018.1441928.